Future directions in glioblastoma: the potential role of TKIs

Share :
Published: 9 May 2019
Views: 2405
Prof Roger Stupp, Dr Giuseppe Lombardi

Current treatment options are very limited for recurrent glioblastoma. Not only are these a complex tumour type, their location adds an additional factor: the blood-brain barrier, which can prevent pharmacotherapies from reaching tumour cells.

The REGOMA trial was a phase 2 trial to investigate the efficacy and safety of regorafenib in treating recurrent glioblastoma after radiotherapy/temozolomide. The highly vascular nature of the tumour renders regorafenib a potentially efficacious agent, and the results of this phase 2 trial indicate a possible use in cases of relapsed glioblastoma.

Chaired by Professor Roger Stupp and featuring guest author Dr Giuseppe Lombardi, this session summarises the key findings of the trial and explores the potential future of regorafenib in the treatment of glioblastoma.

This independent educational activity is supported by an educational grant from Bayer Pharmaceuticals.

The educational content has been developed by Liberum IME and validated by an independent steering committee; Bayer Pharmaceuticals have had no influence on the content of this education.

If you are from Spain or Italy and want to listen to advice from experts from your country please visit Oncology knowledge into practice.